comprehensive -WSS

comprehensive

author：fashion 2025-09-02 08:22:33 - browse：832

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Elizabeth Holmes banned from government health programs

leisure time

WSS

eGenesis tests gene

Doctors on social media are being harassed and cyberbullied

Copay coupons to count toward deductibles, after Biden court move

Readout Newsletter: Merck, J&J, and long Covid

Having children helps parents live longer, especially after age 80

Ebola vaccine can save some who are already sick, per new study

focus

comprehensive

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Congress considering partial increase for doctor pay in Medicare

George Santos makes 1st court appearance after pleading not guilty to 13 counts

NIH director takes cautious approach to Biden drug pricing priority

Moonlake's readout produced a cash windfall. Risks remain

EU regulator recommends expanding Mounjaro approval to obesity

Alkermes shareholders re

Ebola vaccine can save some who are already sick, per new study

In age of alternative facts, a scholarly course on calling out crap

Eli Lilly, Pfizer, and others want in on the online prescription market

entertainment

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Elizabeth Holmes banned from government health programs

Humana cuts profit projections as Medicare Advantage costs soar

The surgeon had a dilemma only a Nazi medical text could resolve

Too many hospitalized Covid

Why doctors need education on FDA device approval process

hotspot

leisure time

entertainment

explore